Active Biotech to Present at the UBS 2007 Global Life Sciences Conference
The presentation will include laquinimod, an oral immunomodulatory drug for the treatment of Multiple Sclerosis, which is licensed to Teva Pharmaceutical Industries Ltd and recently started Phase III studies; ANYARA, Active Biotech's novel concept for the treatment of primarily renal cancer, currently in Phase II; and other key projects in clinical development; TASQ for prostate cancer; 57-57 for Lupus (SLE) and RhuDex® (licensed to MediGene AG) for Rheumatoid Arthritis. The presentation will also cover the preclinical I-3D project in co-development with Chelsea Therapeutics.
The audio and slide presentation will be webcasted live and can be accessed via the Active Biotech web site.
The presentation will take place on September 26, at 12:30 pm US Eastern Time / 18:30 Central European Time.
About Active Biotech
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA. In addition, the autoimmunity project I-3D is in preclinical development.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50